Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia

被引:110
作者
Elting, Linda S. [1 ]
Lu, Charles
Escalante, Carmelita P.
Giordano, Sharon H.
Trent, Jonathan C.
Cooksley, Catherine
Avritscher, Elenir B. C.
Shih, Ya-Chen Tina
Ensor, Joe
Bekele, B. Nebiyou
Gralla, Richard J.
Talcott, James A.
Rolston, Kenneth
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Sect Hlth Serv Res, Houston, TX 77030 USA
关键词
D O I
10.1200/JCO.2007.13.8222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We retrospectively compared the outcomes and costs of outpatient and inpatient management of low-risk outpatients who presented to an emergency department with febrile neutropenia ( FN). Patients and Methods A single episode of FN was randomly chosen from each of 712 consecutive, low-risk solid tumor outpatients who had been treated prospectively on a clinical pathway ( 1997-2003). Their medical records were reviewed retrospectively for overall success ( resolution of all signs and symptoms of infection without modification of antibiotics, major medical complications, or intensive care unit admission) and nine secondary outcomes. Outcomes were assessed by physician investigators who were blinded to management strategy. Outcomes and costs ( payer's perspective) in 529 low- risk outpatients were compared with 123 low- risk patients who were psychosocially ineligible for outpatient management ( no access to caregiver,telephone, or transportation; residence > 30 minutes from treating center; poor compliance with previous outpatient therapy) using univariate statistical tests. Results Overall success was 80% among low- risk outpatients and 79% among low- risk inpatients. Response to initial antibiotics was 81% among outpatients and 80% among inpatients ( P =.94); 21% of those initially treated as outpatients subsequently required hospitalization. All patients ultimately responded to antibiotics; there were no deaths. Serious complications were rare ( 1%) and equally frequent between the groups. The mean cost of therapy among inpatients was double that of outpatients ($ 15,231 v $ 7,772; P <.001). Conclusion Outpatient management of low- risk patients with FN is as safe and effective as inpatient management of low- risk patients and is significantly less costly.
引用
收藏
页码:606 / 611
页数:6
相关论文
共 47 条
[21]   ORAL CIPROFLOXACIN THERAPY FOR INFECTIONS IN CANCER-PATIENTS [J].
HARON, E ;
ROLSTON, KVI ;
CUNNINGHAM, C ;
HOLMES, F ;
UMSAWASDI, T ;
BODEY, GP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (06) :955-962
[22]   CAUSES OF DEATH IN ACUTE LEUKEMIA - A 10-YEAR STUDY OF 414 PATIENTS FROM 1954-1963 [J].
HERSH, EM ;
BODEY, GP ;
NIES, BA ;
FREIREIC.EJ .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 193 (02) :105-&
[23]  
Hidalgo M, 1999, CANCER, V85, P213, DOI 10.1002/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO
[24]  
2-D
[25]   Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study [J].
Innes, HE ;
Smith, DB ;
O'Reilly, SM ;
Clark, PI ;
Kelly, V ;
Marshall, E .
BRITISH JOURNAL OF CANCER, 2003, 89 (01) :43-49
[26]   AZTREONAM THERAPY IN NEUTROPENIC PATIENTS WITH CANCER [J].
JONES, PG ;
ROLSTON, KVI ;
FAINSTEIN, V ;
ELTING, L ;
WALTERS, RS ;
BODEY, GP .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (02) :243-248
[27]   Bacterial infections in low-risk, febrile neutropenic patients - Over a decade of experience at a comprehensive cancer center [J].
Kamana, M ;
Escalante, C ;
Mullen, CA ;
Frisbee-Hume, S ;
Rolston, KVI .
CANCER, 2005, 104 (02) :422-426
[28]   Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia [J].
Karthaus, M ;
Egerer, G ;
Kullmann, KH ;
Ritter, J ;
Jürgens, H .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (07) :501-504
[29]   Risk assessment and treatment of low-risk patients with febrile neutropenia [J].
Kern, WV .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (04) :533-540
[30]   The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients [J].
Klastersky, J ;
Paesmans, M ;
Rubenstein, EB ;
Boyer, M ;
Elting, L ;
Feld, R ;
Gallagher, J ;
Herrstedt, J ;
Rapoport, B ;
Rolston, K ;
Talcott, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :3038-3051